What Is Her
Risk Of Late
Distant
Recurrence?

Order Breast
Cancer
IndexOrder Breast Cancer IndexOrder Breast Cancer Index

Breast Cancer Index® Prognostic Validation For Risk Of Late Distant Recurrence

Breast Cancer Index Has Extensive Validation Demonstrating Its Ability To Determine Risk Of Late (Post 5-Year) Distant Recurrence In Women With Early-Stage, Hormone Receptor–Positive (HR+) Breast Cancer

The ability of Breast Cancer Index to determine an individual’s risk of late distant recurrence has been validated across multiple studies, including various treatment histories, and a mix of pre- and post-menopausal patients.1-3

For patients completing standard adjuvant endocrine therapy who are disease-free at 5 years.

Distant Recurrence Rate From Years 5 to 10 As Measured By Breast Cancer Index

Read the Full Breast Cancer Index Prognostic Validation Studies

1. Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence »

2. Prediction of late distant recurrence in estrogen receptor positive breast cancer patients: prospective comparison of the Breast Cancer Index (BCI), Oncotype DX recurrence score, and IHC4 in TransATAC »

3. A novel Breast Cancer Index for prediction of distant recurrence in HR+ early stage breast cancer with 1 to 3 positive nodes »

References: 1. Zhang Y, et al. Clin Cancer Res. 2013;19(15):4196‑205. 2. Sgroi, et al., Lancet Oncology, 2013,14(11):1067‑1076. 3. Zhang Y et al. Clin Cancer Res. 2017 Dec 1;23(23):7217‑7224.

Back To All
Back to Top
Order Breast Cancer Index
Order Breast
Cancer Index
Resources For Providers
Resources
For Providers